Australia's Leading Ophthalmic Magazine Since 1975

     Free Sign Up     

Australia's Leading Ophthalmic Magazine Since 1975

     Free Sign Up     

Valeant increases offer for Allergan to $US55 billion

On 30 May, Valeant Pharmaceuticals International Inc again increased its offer to acquire Allergan Inc under which each Allergan share would be exchanged for $US72.00 in cash and 0.83 shares of Valeant common stock.

That increases Valeant's offer to approximately $55 billion in cash and stock, up from the approximately $49 billion the company had offered two days prior.

It is the second time Valeant increased its offer to Allergan stockholders after it first proposed an unsolicited merger with Allergan on 22 April.

According to a statement from Valeant, the offer is subject to prompt good faith negotiation of a merger agreement between Valeant and Allergan, and shareholders will continue to be able to elect cash and/or Valeant stock, subject to proration.

Pershing Square, Allergan's largest shareholder with a 9.7 per cent stake, has agreed to elect only stock consideration and receive no cash consideration in the transaction and exchange its Allergan shares for Valeant shares at a 1.22659 exchange ratio, based on 29-May closing stock prices of Allergan and Valeant.


Editor's Suggestion
Hot Stories


Subscribe for Insight in your Inbox

Get Insight with the latest in industry news, trends, new products, services and equipment!